Molecular mechanisms of resistance to the HER1/EGFR tyrosine kinase inhibitor erlotinib HCI in human cell lines.

被引：0
|
作者：
Perez-Soler, R
Ling, YH
Lia, M
Kroog, G
Dai, Q
Zou, Y
Haigentz, M
Iwata, KK
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] OSI Pharmaceut, Farmingdale, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：292S / 292S
页数：1
相关论文
共 50 条
  • [1] Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib
    Kim, JC
    Ali, MA
    Nandi, A
    Mukhopadhyay, P
    Choy, H
    Cao, C
    Saha, D
    INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 2005, 42 (06): : 358 - 365
  • [2] Growth response of human colorectal tumour cell lines to treatment with BIBW2992, an irreversible EGFR/HER1 and HER-2 tyrosine kinase inhibitor
    Khelwatty, S.
    Essapen, S.
    Seddon, A. M.
    Modjtahedi, H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 51 - 51
  • [3] Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
    Tartarone, Alfredo
    Lazzari, Chiara
    Lerose, Rosa
    Conteduca, Vincenza
    Improta, Giuseppina
    Zupa, Angela
    Bulotta, Alessandra
    Aieta, Michele
    Gregorc, Vanesa
    LUNG CANCER, 2013, 81 (03) : 328 - 336
  • [4] Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines
    Dai, Q
    Ling, YH
    Lia, M
    Zou, YY
    Kroog, G
    Iwata, KK
    Perez-Soler, R
    CLINICAL CANCER RESEARCH, 2005, 11 (04) : 1572 - 1578
  • [5] Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
    Jianping Chen
    Melissa Smith
    Kenneth Kolinsky
    Violeta Adames
    Nila Mehta
    Luke Fritzky
    Mohammad Rashed
    Eric Wheeldon
    Michael Linn
    Brian Higgins
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 651 - 659
  • [6] Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
    Chen, Jianping
    Smith, Melissa
    Kolinsky, Kenneth
    Adames, Violeta
    Mehta, Nila
    Fritzky, Luke
    Rashed, Mohammad
    Wheeldon, Eric
    Linn, Michael
    Higgins, Brian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) : 651 - 659
  • [7] HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme
    Raizer, RJ
    JOURNAL OF NEURO-ONCOLOGY, 2005, 74 (01) : 77 - 86
  • [8] HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme
    Jeffrey J. Raizer
    Journal of Neuro-Oncology, 2005, 74 : 77 - 86
  • [9] PHARMACOPHORE MODELING OF DIVERSE CLASSES OF EGFR (HER1) TYROSINE KINASE INHIBITORS
    Gupta, Amit K.
    Dev, Kapil
    Saxena, Anil K.
    MEDICINAL CHEMISTRY RESEARCH, 2010, 19 : S49 - S49
  • [10] Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines.
    Perez-Soler, R
    Piperdi, B
    Haigentz, M
    Ling, YH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 623S - 623S
12345